Tango Therapeutics (TNGX) closed at $21.89 on November 18, 2026, down 1.0% from the previous close, on volume of 2,457,935 shares (30-day average 3,833,184).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | 6 Leg Call/Put Combo Calendar | Bunched | 4,500 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Tango Therapeutics (TNGX)
TipRanks (Wed, 18-Nov 8:21 AM ET)
Tango Therapeutics: Buy Rating and $46 Price Target Maintained Ahead of ERAS-0015 Data
TipRanks (Tue, 17-Nov 10:55 AM ET)
PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month
Globe Newswire (Mon, 16-Nov 11:42 AM ET)
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Market Chameleon (Fri, 23-Oct 3:06 AM ET)
Globe Newswire (Fri, 23-Oct 6:30 AM ET)
Globe Newswire (Fri, 16-Oct 7:00 AM ET)
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Tango Therapeutics trades on the NASDAQ stock market under the symbol TNGX.
As of November 18, 2026, TNGX stock price declined to $21.89 with 2,457,935 million shares trading.
TNGX has a beta of 1.00, meaning it tends to be more sensitive to market movements. TNGX has a correlation of 0.02 to the broad based SPY ETF.
TNGX has a market cap of $3.71 billion. This is considered a Mid Cap stock.
In the last 3 years, TNGX traded as high as $34.39 and as low as $1.03.
The top ETF exchange traded funds that TNGX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
TNGX has outperformed the market in the last year with a return of +174.3%, while the SPY ETF gained +10.8%. However, in the most recent history, TNGX shares have underperformed the stock market with its stock returning -13.4% in the last 3 month period and -5.5% for the last 2 week period, while SPY has returned -5.3% and -3.2%, respectively.
TNGX support price is $20.80 and resistance is $23.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNGX shares will trade within this expected range on the day.